Clinical Trial Detail

NCT ID NCT03101254
Title LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

melanoma

Therapies

Cobimetinib + LY3022855 + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST